Table 2.
Six-month follow-up clinical and instrumental data of the five patients with psoriasis-related myocarditis.
| Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | |
|---|---|---|---|---|---|
| Age/sex | 67/M | 52/M | 54/M | 65/M | 44/M |
| Therapy | Az + Pr | Az + Pr | Az + Pr | SK | SK |
| Severity of skin psoriasis | Mild | Mild | Mild | Healed | Healed |
| Presence of arthritis | No | No | Yes (improved) |
No | Yes (improved) |
| Eye involvement | No | No | No | Healed | Healed |
| NYHA Class | II | II | II | I | I |
| ECG | Normal | Sinus rhythm | SVT, PVC | Normal | Normal |
| 2D-Echocardiogram | |||||
| LVEDD (mm) | 59 | 56 | 50 | 55 | 51 |
| LVEF (%) | 47 | 49 | 50 | 55 | 55 |
| Left atrium (volume, mL) | 62 | 45 | 53 | 40 | 50 |
| E/E’ ratio | 13 | 11 | 12 | 10 | 8 |
| TAPSE (mm) | 19 | 20 | 23 | 25 | 24 |
| Pericardial effusion | No | No | No | No | No |
| Cardiac magnetic resonance | |||||
| LVEDV (mL/m2) | 98.7 | 83.0 | 72.5 | 99.9 | 82.7 |
| LVESV (mL/m2) | 52.6 | 42.0 | 34.4 | 45.2 | 37.9 |
| LVEF % | 46.7 | 49.2 | 50.5 | 54.3 | 55.2 |
| MWT | 14 | 11 | 9 | 11 | 13 |
| LV mass (g/m2) | 75 | 68.5 | 63 | 69.3 | 88.5 |
| Edema | No | No | No | No | No |
| LGE | Yes | No | No | Yes | Yes |
| T1 global ± SD (ms) | 1010 ± 117 | 970 ± 101 | 982 ± 106 | 980 ± 102 | 1030 ± 62 |
| T2 global ± SD (ms) | 41 ± 5 | 46 ± 6 | 49 ± 9 | 42 ± 5 | 46 ± 7 |
Az, azathioprine; Pr, prednisone; SK, secukinumab; SVT, supraventricular tachycardia; PVC, premature ventricular contraction; LVEDD, left-ventricular and diastolic diameter; LVEF, left-ventricular ejection fraction; E/E’ ratio, ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (E’); TAPSE, tricuspid annular-plane systolic excursion; LVEDV, left-ventricular end-diastolic volume; LVESV, left-ventricular end-systolic volume; MWT, maximal wall thickness; LV mass, left-ventricular mass; LGE, late gadolinium enhancement; SD, standard deviation.